G1 Therapeutics (NASDAQ:GTHX) Given Hold Rating at Needham & Company LLC

G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “hold” rating restated by equities researchers at Needham & Company LLC in a report issued on Wednesday, Benzinga reports.

A number of other equities research analysts also recently weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $3.00 price target (down from $5.00) on shares of G1 Therapeutics in a research report on Monday, June 24th. HC Wainwright cut their price objective on shares of G1 Therapeutics from $9.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, June 25th.

G1 Therapeutics Stock Performance

Shares of NASDAQ:GTHX traded up $2.81 during trading on Wednesday, reaching $7.06. 34,804,023 shares of the stock were exchanged, compared to its average volume of 1,624,122. The firm has a market cap of $369.10 million, a PE ratio of -11.40 and a beta of 1.53. The company has a current ratio of 2.94, a quick ratio of 2.55 and a debt-to-equity ratio of 1.34. G1 Therapeutics has a 12 month low of $1.08 and a 12 month high of $7.09. The stock has a 50-day moving average price of $3.12 and a 200-day moving average price of $3.63.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. abrdn plc acquired a new stake in G1 Therapeutics during the 4th quarter worth approximately $1,293,000. Choreo LLC bought a new position in shares of G1 Therapeutics during the fourth quarter valued at $107,000. Jump Financial LLC acquired a new position in shares of G1 Therapeutics during the fourth quarter worth $105,000. Financial Advocates Investment Management bought a new stake in shares of G1 Therapeutics in the fourth quarter worth $39,000. Finally, Capstone Investment Advisors LLC acquired a new stake in G1 Therapeutics in the fourth quarter valued at $76,000. 24.21% of the stock is currently owned by institutional investors and hedge funds.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.